Raymed Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 24-10-2024
- Paid Up Capital ₹ 1.71 M
as on 24-10-2024
- Company Age 30 Year, 7 Days
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 4.46 Cr
as on 24-10-2024
- Satisfied Charges ₹ 8.66 M
as on 24-10-2024
- Revenue 23.29%
(FY 2023)
- Profit 91.08%
(FY 2023)
- Ebitda 71.79%
(FY 2023)
- Net Worth 34.24%
(FY 2023)
- Total Assets 42.20%
(FY 2023)
About Raymed Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 1.71 M.
The company currently has active open charges totaling ₹4.46 Cr. The company has closed loans amounting to ₹8.66 M, as per Ministry of Corporate Affairs (MCA) records.
Tarsem Ruby, Veeta Sharma, and Shivansh Sharma serve as directors at the Company.
- CIN/LLPIN
U24231CH1995PLC015598
- Company No.
015598
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
10 Jan 1995
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chandigarh
Industry
Company Details
- Location
Chandigarh, India
- Telephone
- Email Address
- Website
- Social Media
What products or services does Raymed Pharmaceuticals Limited offer?
Raymed Pharmaceuticals Limited offers a wide range of products and services, including Common Disease Medicines, Eye Drops, Computer, IT & Software Training, Computer Language Training Services, Tropicamide Drops, Sodium Hyaluronate Ophthalmic Solution, Pain Relief Drugs & Pharmaceuticals, Anti Inflammatory Drugs, Eye Care Medicines, Herbal Eye Drops.
Who are the key members and board of directors at Raymed Pharmaceuticals?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Shivansh Sharma  | Director | 17-Apr-2015 | Current |
| Tarsem Ruby | Director | 10-Jan-1995 | Current |
| Veeta Sharma | Director | 30-Mar-1997 | Current |
Financial Performance of Raymed Pharmaceuticals.
Raymed Pharmaceuticals Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 23.29% increase. The company also saw a substantial improvement in profitability, with a 91.08% increase in profit. The company's net worth Soared by an impressive increase of 34.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Raymed Pharmaceuticals?
In 2023, Raymed Pharmaceuticals had a promoter holding of 40.67% and a public holding of 59.33%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Raymed Ophthalmic Private LimitedActive 5 years 8 monthsTarsem Ruby and Shivansh Sharma are mutual person
- Raymzon Trade Links Private LimitedActive 4 years 5 months
Tarsem Ruby, Veeta Sharma and 1 more are mutual person
- Aquavision Pharmaceuticals Private LimitedActive 4 years 3 months
Tarsem Ruby and Shivansh Sharma are mutual person
- Ayuray Organics Private LimitedActive 4 years 6 months
Tarsem Ruby and Shivansh Sharma are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Axis Bank Limited Creation Date: 30 Aug 2023 | ₹6.00 M | Open |
Hdfc Bank Limited Creation Date: 19 Jun 2023 | ₹8.00 M | Open |
Hdfc Bank Limited Creation Date: 26 Dec 2022 | ₹3.00 Cr | Open |
How Many Employees Work at Raymed Pharmaceuticals?
Raymed Pharmaceuticals has a workforce of 8 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Raymed Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Raymed Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
